Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessment

Objectives Patient and public involvement (PPI) in clinical research has a well-established infrastructure in the UK, and while there has been good progress within pharmaceutical-industry-sponsored research, further improvements are still needed. This review aims to share learnings from quality asse...

Full description

Saved in:

Bibliographic Details
Published in:	BMJ open Vol. 13; no. 8; p. e071339
Main Authors:	Dews, Sally-Anne, Bassi, Adit, Buckland, Sean, Clements, Lucy, Daley, Rachel, Davies, Angela, Evett, Sophie, Howland, Samantha, Kinloch, Emma, Phillips, Berkeley, Powell, Gareth, Preston, Jennifer, Sterniczuk, Kamil, Bohm, Natalie
Format:	Journal Article
Language:	English
Published:	London BMJ Publishing Group LTD 23-08-2023 BMJ Publishing Group
Series:	Original research
Subjects:	Collaboration Medical research Patient-Centred Medicine Patients Pharmaceutical industry Quality control Stakeholders United Kingdom > UK
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objectives Patient and public involvement (PPI) in clinical research has a well-established infrastructure in the UK, and while there has been good progress within pharmaceutical-industry-sponsored research, further improvements are still needed. This review aims to share learnings from quality assessments of historical PPI projects within Pfizer UK to inform future projects and drive PPI progress in the pharmaceutical industry. Design and setting Internal assessments of Pfizer UK PPI projects were conducted to identify all relevant projects across the medicines development continuum between 2017 and 2021. Five sample projects were developed into case studies. Outcome measure Retrospective quality assessments were performed using the Patient Focused Medicines Development (PFMD) Patient Engagement Quality Guidance (PEQG) tool. Recommendations for improvement were developed. Results Retrospective case study analysis and quality framework assessment revealed benefits of PPI to both Pfizer UK and to external partners, as well as challenges and learnings to improve future practice. Recommendations for improvement based on these findings focused on processes and procedures for PPI, group dynamics and diversity for PPI activities, sharing of expertise, the importance of bidirectional and timely feedback, and the use of understandable language in materials. Conclusions PPI in medicines development is impactful and beneficial but is still being optimised in the pharmaceutical industry. Using the PFMD PEQG tool to define gaps, share learnings and devise recommendations for improvement helps to ensure that PPI is genuine and empowering, rather than tokenistic. Ultimately, these recommendations should be acted on to further embed PPI as an integral part of medicines development and health research within the pharmaceutical industry. This article includes a plain language summary in the supplement.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2044-6055 2044-6055
DOI:	10.1136/bmjopen-2022-071339